References
Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376:1321–1331
Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, Thomas M, Kovac J, Spyt T, MacCarthy P, Wendler O, Hildick-Smith D, Davies SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJ, Baumbach A, Daniel T, Gray H, Mullen MJ (2011) Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom transcatheter aortic valve implantation) registry. J Am Coll Cardiol 58:2130–2138
Jakobsen L, Terkelsen CJ, Sondergaard L et al (2018) Short- and long-term mortality and stroke risk after transcatheter aortic valve implantation. Am J Cardiol 121:78–85
National Institute of Neurological D, Stroke rt PASSG (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587
Voelkel N, Hubert ND, Backhaus R, Haberl RL, Hubert GJ (2017) Thrombolysis in postoperative stroke. Stroke 48:3034–3039
D'Anna L, Demir O, Banerjee S, Malik I (2019) Intravenous thrombolysis and mechanical thrombectomy in patients with stroke after TAVI: a report of two cases. J Stroke Cerebrovasc Dis 28:104277
Montarello NJ, Nelson AJ, Sidharta SL, Worthley SG (2016) Intravenous recombinant tissue plasminogen activator therapy for acute basilar artery ischemic stroke following transfemoral transcatheter aortic valve implantation. J Heart Valve Dis 25:14–17
Acknowledgments
We appreciate the cooperation of the patient and her family. We thank Nancy Schatken, BS, MT (ASCP) and Lisa Giles, PhD, from Edanz Group (https://en-author-services.edanzgroup.com/), for editing a draft of this manuscript.
Author information
Authors and Affiliations
Contributions
M. Kosuke was the attending doctor for the present case. M. Kosuke drafted the manuscript. M. Kumiko, T.O., and T.M. helped draft the manuscript. S.F. conceived the study, participated in its coordination, and helped draft the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
S.F. received honoraria from Mitsubishi Tanabe Pharma (Edaravone manufacturer) in 2017 and 2019, and from Eisai Co., Ltd. (Warfarin manufacturer) in 2017, 2018, and 2019. S.F. also received a donation from Eisai Co., Ltd. (Warfarin manufacturer) in 2019.
Ethical approval
Informed consent was obtained from the patient described in this article.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Matsuzono, K., Miura, K., Ozawa, T. et al. Outcome of intravenous rt-PA therapy for a stroke patient during the short-term period after TAVI. Neurol Sci 41, 2625–2627 (2020). https://doi.org/10.1007/s10072-020-04344-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-020-04344-2